Peripheral neuropathy, characterized by numbness, tingling, and often debilitating pain in the extremities, poses a significant challenge for colorectal cancer patients treated with oxaliplatin, a cornerstone chemotherapy agent. The neurotoxic effects of oxaliplatin undermine treatment tolerability and quality of life, frequently prompting dose reductions or discontinuations, which can compromise oncological outcomes. Given duloxetine’s FDA approval and clinical use in treating established chemotherapy-induced neuropathic pain, this trial sought to rigorously test whether initiating duloxetine concomitant with chemotherapy could avert the neuropathic trajectory altogether.

The randomized, double-blind, placebo-controlled trial enrolled 199 adults diagnosed with stage II or III colorectal cancer across 73 cancer centers nationwide in the United States. Participants, confirmed to be free of baseline neuropathy, were stratified to receive either daily duloxetine at dosages of 30 mg or 60 mg, or a matching placebo. Treatment commenced synchronously with the first administration of oxaliplatin and extended through 17 weeks of chemotherapy cycles. The primary endpoint was a composite patient-reported outcome assessing neuropathy severity and onset several weeks post-chemotherapy, thus integrating subjective symptomatology with temporal development.

Contrary to the initial hypothesis, the data compellingly demonstrated no statistically significant or clinically meaningful difference between either duloxetine group and the placebo cohort. Both duloxetine dosages failed to prevent the progression or severity of neuropathic symptoms, indicating that the pharmacologic properties of duloxetine, while symptomatic, are not prophylactic against the neurotoxic insult induced by oxaliplatin. This finding underscores a dissociation between duloxetine’s analgesic modulation once neuropathy emerges and its inability to interrupt the pathophysiological mechanisms initiating nerve injury.

Ellen M. Lavoie Smith, PhD, MSN, Interim Associate Dean of Research and Scholarship at the University of Alabama at Birmingham School of Nursing and chair of the Alliance A221805 study, emphasized the clinical implications: “Although duloxetine is a vital option for treating established painful neuropathy following chemotherapy, our evidence clearly shows it should not be prescribed with the expectation of preventing neuropathy in patients undergoing oxaliplatin treatment.” This pivotal clarification reshapes current clinical practice guidelines and informs oncologists’ therapeutic decision-making during adjuvant chemotherapy planning.

The biological underpinnings of chemotherapy-induced peripheral neuropathy are multifactorial, involving direct axonal damage, mitochondrial dysfunction, oxidative stress, and neuroinflammatory cascades precipitated by agents like oxaliplatin. Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), exerts analgesic effects by modulating central pain pathways but does not appear to counteract the fundamental neurotoxic injury processes. This trial’s outcomes highlight the urgent necessity for novel neuroprotective strategies that arrest or mitigate nerve damage at the cellular and molecular origins.

Moreover, the trial’s rigorous design—including its multi-center enrollment, stringent exclusion of pre-existing neuropathy, and validated patient-reported outcomes—provides high-quality evidence with robust external validity. The use of two duloxetine dosages also permits a nuanced understanding of dose-response dynamics, affirming that neither standard nor escalated doses produce prophylactic benefit. These insights delineate the pharmacodynamic boundaries of duloxetine in this oncological context.

Despite the trial’s negative result for preventative application, duloxetine remains an important therapeutic agent in the symptomatic management of chemotherapy-induced peripheral neuropathic pain. This distinction between treatment and prevention is critical, avoiding off-label use for prophylaxis that lacks empirical support and could expose patients to unnecessary pharmaceutical burden without clinical gain.

The findings carry broader implications for cancer survivorship, as peripheral neuropathy frequently persists as a chronic sequelae that impairs functional status and quality of life long after chemotherapy cessation. Identification of effective preventive interventions remains a high priority in cancer supportive care research. The trial by Alliance A221805 represents a significant step in redirecting focus towards alternative pathways and agents with neuroprotective potential.

Financial support for this study was provided by multiple National Cancer Institute grants, underscoring the importance of federal investment in large-scale, practice-changing oncology trials. The collaboration among leading research networks such as Alliance, ECOG-ACRIN, NRG Oncology, and SWOG exemplifies the integrated effort required to tackle complex clinical questions affecting diverse patient populations.

In summary, the Alliance A221805 trial delivers definitive evidence that duloxetine should not be used as a prophylactic agent to prevent oxaliplatin-induced peripheral neuropathy in colorectal cancer patients. While resting duloxetine’s role firmly in symptom management, this work invigorates the search for innovative neuroprotective therapies and fosters informed clinical guidance to improve cancer care outcomes and survivorship quality.

Subject of Research: People

Article Title: Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study

News Publication Date: 25-Mar-2026

Web References:

• Alliance A221805 Clinical Trial
• JCO Oncology Advances Article

References:

• JCO Oncology Advances: Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study

Image Credits: University of Alabama at Birmingham School of Nursing

Keywords: chemotherapy-induced peripheral neuropathy, duloxetine, oxaliplatin, colorectal cancer, neuropathic pain, chemotherapy side effects, randomized controlled trial, neurotoxicity, cancer treatment, patient-reported outcomes, neuroprotection, analgesic therapy

Acceptance and Commitment Therapy, rooted in mindfulness and behavioral change principles, aims to help individuals embrace difficult experiences rather than avoid them. Traditionally administered in-person, this study’s innovation lies in delivering ACT via group video calls, making therapy accessible and scalable amid the digital transformation of healthcare. This approach is especially compelling for breast cancer patients, who often face emotional turmoil and persistent physical symptoms that disrupt daily functioning.

The randomized clinical trial adopted a semi-experimental design involving 36 breast cancer patients. Participants were sourced from the Maxa Center in Isfahan and then randomly assigned to either the experimental group undergoing ACT or a control group receiving general education and support through virtual sessions. Each therapy session lasted an hour and spanned ten weeks, ensuring comprehensive engagement and consistent exposure to the intervention.

Data collection was structured at three critical timelines: baseline (pre-intervention), immediately post-treatment, and a 12-week follow-up. This schedule allowed researchers to capture both the short-term and potential sustained impacts of the internet-based ACT. The study employed validated checklists and questionnaires targeting key outcome metrics—acceptance of illness, emotional regulation difficulties, severity of symptoms, and how these symptoms interfere with various aspects of patients’ daily lives.

One of the most intriguing findings concerns the acceptance of illness. While patients undergoing internet-based ACT reported increased acceptance over time relative to controls, these differences did not reach statistical significance. This subtlety suggests that while digital ACT may nudge patients towards greater psychological acceptance, larger-scale or longer-duration interventions might be necessary to produce robust effects in this domain.

Conversely, the trial yielded compelling evidence that online ACT significantly ameliorates difficulties in emotion regulation. Breast cancer patients often grapple with intense emotions, including anxiety, sadness, and fatigue. The therapeutic focus on mindfulness and value-driven commitment appears to equip patients with strategies to better navigate these emotional challenges, reducing overall distress and enhancing psychological resilience.

Symptom severity formed another crucial pillar of analysis. The experimental group exhibited marked reductions in psychological symptoms such as fatigue, anxiety, and sadness. Importantly, these improvements were statistically significant and sustained across the study timeline. Physical symptoms like pain and sleep disturbances also declined, although these trends were present in both groups, implying a combined effect of time and general support mechanisms.

Symptom interference—how symptoms disrupt core functions like mood, social relationships, and daily activities—is a critical barometer of quality of life. Although patients receiving internet-based ACT showed higher rates of improvement in symptom interference, the findings did not achieve statistical significance. This outcome hints at the complexity of symptom management in cancer care and underscores the necessity for multifaceted therapeutic strategies.

A notable aspect of the study is its focus on delivering psychological support remotely. Telehealth interventions have gained immense momentum, particularly in the wake of the COVID-19 pandemic, as they overcome barriers related to accessibility and convenience. This trial reinforces the viability of virtual platforms for conducting structured psychotherapy, even in populations coping with severe medical conditions.

From a methodological standpoint, the use of multivariate repeated measures ANOVA allowed the researchers to thoroughly examine the interaction effects of treatment and time. This statistical rigor adds credibility to the findings, ensuring that observed changes are attributed with confidence to the intervention rather than external variables or chance.

The study’s limitations, however, warrant consideration. The sample size, limited to 36 participants, restricts generalizability and the power to detect smaller effect sizes. Future research could benefit from larger cohorts, diversified demographics, and potentially incorporating biomarker assessments to explore physiological correlates of psychological change.

Importantly, the ethical framework guiding the trial was robust. Approval was secured from the ethics committee of the School of Medicine – Isfahan University of Medical Sciences, and the study was duly registered with the Iranian Registry of Clinical Trials. This adherence to ethical norms ensures participant welfare and scientific integrity throughout the research process.

In conclusion, this research marks a significant step forward in integrating internet-based psychological therapies in oncology. It suggests that Acceptance and Commitment Therapy, when delivered virtually, holds promise in mitigating emotional distress and symptom burden among breast cancer patients. While some outcomes did not reach statistical significance, the overall trend underscores the therapeutic potential of digital ACT and merits further exploration through expansive, multi-center trials.

The convergence of psychological science and digital health technologies offers exciting frontiers, particularly for chronic disease management where sustained patient engagement is challenging. As healthcare ecosystems increasingly embrace telemedicine, interventions like internet-based ACT could become pivotal tools in holistic cancer care, enhancing not only survival but also the quality of life for millions of patients worldwide.

Subject of Research: The effectiveness of internet-based Acceptance and Commitment Therapy on acceptance of illness, emotion regulation, symptom severity reduction, and symptom interference with function in patients with breast cancer.

Article Title: The effectiveness of internet-based acceptance and commitment therapy on acceptance of illness, emotion regulation, symptom severity reduction, and symptoms interference with function in patients with breast cancer

Article References:
Mirzaei, S., Bagherian-Sararoudi, R., Emami, M.H.D. et al. The effectiveness of internet-based acceptance and commitment therapy on acceptance of illness, emotion regulation, symptom severity reduction, and symptoms interference with function in patients with breast cancer. BMC Psychiatry 25, 599 (2025). https://doi.org/10.1186/s12888-025-06823-2

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-06823-2